Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cordula Zeller

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
EURASIP Journal on Bioinformatics & Systems Biology|January 17, 2009
A Bayesian network view on nested effects modelsCordula Zeller, Holger Fröhlich, Achim Tresch
Advances in Therapy|June 21, 2017
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical TrialsSven Kohler, Cordula Zeller, Hristo Iliev, et al.
Diabetes Care|June 17, 2018
Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus GlimepirideSven Kohler, Stefan Kaspers, Afshin Salsali, et al.
Cardiovascular Diabetology|September 7, 2013
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic controlMartin Ridderstråle, Robbyna Svaerd, Cordula Zeller, et al.
The Lancet. Diabetes & Endocrinology|June 21, 2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trialMartin Ridderstråle, Knut Robert Andersen, Cordula Zeller, et al.
Diabetes Care|October 2, 2014
Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertensionIlkka Tikkanen, Kirsi Narko, Cordula Zeller, et al.
Journal of the American College of Cardiology|September 4, 2024
Competing Risks in Clinical Trials: Do They Matter and How Should We Account for Them?John Gregson, Stuart J Pocock, Stefan D Anker, et al.
ESC Heart Failure|September 11, 2020
Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOMEPierpaolo Pellicori, Anne Pernille Ofstad, David Fitchett, et al.
Hypertension (Dallas, Tex. : 1979)|December 16, 2016
Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive MedicationGiuseppe Mancia, Christopher P Cannon, Ilkka Tikkanen, et al.
Circulation|April 14, 2025
Patient-Reported Outcomes as End Points in Heart Failure TrialsJaved Butler, Muhammad Shariq Usman, Charu Gandotra, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
EURASIP Journal on Bioinformatics & Systems Biology|January 17, 2009
A Bayesian network view on nested effects modelsCordula Zeller, Holger Fröhlich, Achim Tresch
Advances in Therapy|June 21, 2017
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical TrialsSven Kohler, Cordula Zeller, Hristo Iliev, et al.
Diabetes Care|June 17, 2018
Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus GlimepirideSven Kohler, Stefan Kaspers, Afshin Salsali, et al.
Cardiovascular Diabetology|September 7, 2013
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic controlMartin Ridderstråle, Robbyna Svaerd, Cordula Zeller, et al.
The Lancet. Diabetes & Endocrinology|June 21, 2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trialMartin Ridderstråle, Knut Robert Andersen, Cordula Zeller, et al.
Diabetes Care|October 2, 2014
Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertensionIlkka Tikkanen, Kirsi Narko, Cordula Zeller, et al.
Journal of the American College of Cardiology|September 4, 2024
Competing Risks in Clinical Trials: Do They Matter and How Should We Account for Them?John Gregson, Stuart J Pocock, Stefan D Anker, et al.
ESC Heart Failure|September 11, 2020
Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOMEPierpaolo Pellicori, Anne Pernille Ofstad, David Fitchett, et al.
Hypertension (Dallas, Tex. : 1979)|December 16, 2016
Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive MedicationGiuseppe Mancia, Christopher P Cannon, Ilkka Tikkanen, et al.
Circulation|April 14, 2025
Patient-Reported Outcomes as End Points in Heart Failure TrialsJaved Butler, Muhammad Shariq Usman, Charu Gandotra, et al.
Pageof 4